Alembic Global Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALEMBIC GLOBAL
ALEMBIC GLOBAL has one approved drug.
Summary for Alembic Global
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Alembic Global: | See patent lawsuits for Alembic Global |
Drugs and US Patents for Alembic Global
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic Global | TREPROSTINIL | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211574-002 | Feb 11, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alembic Global | TREPROSTINIL | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211574-004 | Feb 11, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alembic Global | TREPROSTINIL | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211574-003 | Feb 11, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alembic Global | TREPROSTINIL | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211574-001 | Feb 11, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

